Author's response
Ann Allergy Asthma Immunol
.
2023 Sep;131(3):399.
doi: 10.1016/j.anai.2023.06.019.
Authors
Sarina Tanimoto
1
,
Michael Kaliner
2
,
Anne K Ellis
3
,
Richard Lowenthal
4
Affiliations
1
ARS Pharmaceuticals, Inc, San Diego, California. Electronic address: sarinat@ars-pharma.com.
2
Institute for Asthma and Allergy, Chevy Chase, Maryland.
3
Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: anne.ellis@kingstonhsc.ca.
4
ARS Pharmaceuticals, Inc, San Diego, California.
PMID:
37661173
DOI:
10.1016/j.anai.2023.06.019
No abstract available
Publication types
Letter